Advertisement

Immunogenetics

, Volume 70, Issue 8, pp 547–551 | Cite as

Absence of the tag polymorphism for the risk haplotype HLA-DR2 for multiple sclerosis in Wixárika subjects from Mexico

  • G. V. González-Enríquez
  • B. M. Torres-Mendoza
  • J. Márquez-Pedroza
  • M. A. Macías-Islas
  • G. G. Ortiz
  • J. A. Cruz-Ramos
Short Communication

Abstract

The HLA-DRB1*15:01 allele has a demonstrated risk for the development of multiple sclerosis (MS) in most populations around the world. The single nucleotide polymorphism (SNP) rs3129934 is found in linkage disequilibrium with the risk haplotype formed by the HLA-DRB1*15:01 and HLA-DQB1*06:02 alleles, and it is considered a reliable marker of the presence of this haplotype. Native Americans have a null or low prevalence of MS. In this study, we sought to identify the frequency of rs3129934 in the Wixárika ethnic group as well as in Mestizo (mixed race) patients with MS and in controls from western Mexico. Through real-time polymerase chain reaction (PCR) using TaqMan probes, we analyzed the allele and genotype frequencies of rs3129934 in Mestizo individuals with and without MS and in 73 Wixárika subjects from the state of Jalisco, Mexico. The Wixárika subjects were homozygote for the C allele of rs3129934. The allele and genotype frequency in Mestizos with MS was similar to that of other MS populations with Caucasian ancestry. The absence of the T risk allele rs3129934 (associated with the haplotype HLA-DRB1*15:01, HLA-DQ1*06:02) in this sample of Wixárika subjects is consistent with the unreported MS in this Amerindian group, related to absence of such paramount genetic risk factor.

Keywords

Multiple sclerosis HLA-DR2 haplotype HLA-DRB1*15:01 HLA-DQB1*06:02 Native Americans Caucasic Genetic admixture 

Notes

Acknowledgements

The authors thank Dr. Horacio Rivera Ramírez for his review of the manuscript. Thanks to the Support Unit for Indigenous Communities (http://uaci.udg.mx/) from the University of Guadalajara especially to Dra. Lina Magdalena Gómez Contreras and César Carrillo for their collaboration in the sample collection.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. Alaez C, Infante E, Pujol J, Duran C, Navarro JL, Gorodezky C (2002) Molecular analysis of HLA-DRB1, DQA1, DQB1, DQ promoter polymorphism and extended class I/class II haplotypes in the Seri Indians from Northwest Mexico. Tissue Antigens 59(5):388–396.  https://doi.org/10.1034/j.1399-0039.2002.590505.x CrossRefPubMedGoogle Scholar
  2. Alcina A, de Abad-Grau MM, Fedetz M et al (2012) Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One 7(1):1–9.  https://doi.org/10.1371/journal.pone.0029819 CrossRefGoogle Scholar
  3. Arnaiz-Villena A, Vargas-Alarcon G, Granados J, Gomez-Casado E, Longas J, Gonzalez-Hevilla M, Zuniga J, Salgado N, Hernandez-Pacheco G, Guillen J, Martinez-Laso J (2000) HLA genes in Mexican Mazatecans, the peopling of the Americas and the uniqueness of Amerindians. Tissue Antigens 56(5):405–416.  https://doi.org/10.1034/j.1399-0039.2000.560503.x CrossRefPubMedGoogle Scholar
  4. Arnaiz-Villena A, Palacio-Grüber J, Muñiz E, Rey D, Recio MJ, Campos C, Martinez-Quiles N, Martin-Villa JM, Martinez-Laso J (2016) HLA-DMB in Amerindians: specific linkage of DMB*01:03:01/DRB1 alleles. Hum Immunol 77(5):389–394.  https://doi.org/10.1016/j.humimm.2016.02.011 CrossRefPubMedGoogle Scholar
  5. Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, O'Mahony J, Magalhaes S, Hanwell H, Vieth R, Tellier R, Vincent T, Disanto G, Ebers G, Wambera K, Connolly MB, Yager J, Mah JK, Booth F, Sebire G, Callen D, Meaney B, Dilenge ME, Lortie A, Pohl D, Doja A, Venketaswaran S, Levin S, MacDonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Cooper P, Grand'Maison F, Baird JB, Bhan V, Marrie RA (2011) Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 10(5):436–445.  https://doi.org/10.1016/S1474-4422(11)70045-X CrossRefPubMedGoogle Scholar
  6. Bettencourt A, Carvalho C, Leal B, Brás S, Lopes D, Martins da Silva A, Santos E, Torres T, Almeida I, Farinha F, Barbosa P, Marinho A, Selores M, Correia J, Vasconcelos C, Costa PP, da Silva BM (2015) The protective role of HLA-DRB1(∗)13 in autoimmune diseases. J Immunol Res 2015:948723.  https://doi.org/10.1155/2015/948723 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Comabella M, Craig DW, Carmiña-Tato M et al (2008) Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One 3(10):1–9.  https://doi.org/10.1371/journal.pone.0003490 CrossRefGoogle Scholar
  8. Cristiano E, Rojas JI (2017) Multiple sclerosis epidemiology in Latin America: an updated survey. Mult Scler J Exp Transl Clin 3(2):205521731771505.  https://doi.org/10.1177/2055217317715050 Google Scholar
  9. de Bakker PIW, McVean G, Sabeti PC et al (2006) A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 38(10):1166–1172.  https://doi.org/10.1038/ng1885 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Flores J, González S, Morales X, Yescas P, Ochoa A, Corona T (2012) Absence of multiple sclerosis and demyelinating diseases among Lacandonians, a pure Amerindian ethnic group in Mexico. Mult Scler Int 2012:292631.  https://doi.org/10.1155/2012/292631 PubMedPubMedCentralGoogle Scholar
  11. Fragoso YD (2014) Modifiable environmental factors in multiple sclerosis. Arq Neuropsiquiatr 72(11):889–894.  https://doi.org/10.1590/0004-282X20140159 CrossRefPubMedGoogle Scholar
  12. Garg N, Smith TW (2015) An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 5(9):1–13.  https://doi.org/10.1002/brb3.362 CrossRefGoogle Scholar
  13. Grady CJ, Furst PT (2011) Ethnoscience, genetics, and Huichol origins: new evidence provides congruence. Ethnohistory 58(2):263–291.  https://doi.org/10.1215/00141801-1163037 CrossRefGoogle Scholar
  14. Holling TM, Schooten E, Van Den Elsen PJ (2004) Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol 65(4):282–290.  https://doi.org/10.1016/j.humimm.2004.01.005 CrossRefPubMedGoogle Scholar
  15. International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A et al (2007) Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. N Engl J Med 357(9):851–862.  https://doi.org/10.1056/NEJMoa073493
  16. International Multiple Sclerosis Genetics Consortium, Moutsianas L, Jostins L et al (2015) Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet 47(10):1107–1113.  https://doi.org/10.1038/ng.3395
  17. Kister I, Chamot E, Salter a R et al (2013) Disability in multiple sclerosis: a reference for patients and clinicians. Neurology 80(11):1018–1024.  https://doi.org/10.1212/WNL.0b013e3182872855 CrossRefPubMedPubMedCentralGoogle Scholar
  18. Martinelli-Boneschi F, Esposito F, Brambilla P, Lindström E, Lavorgna G, Stankovich J, Rodegher M, Capra R, Ghezzi A, Coniglio G, Colombo B, Sorosina M, Martinelli V, Booth D, Oturai AB, Stewart G, Harbo HF, Kilpatrick TJ, Hillert J, Rubio JP, Abderrahim H, Wojcik J, Comi G (2012) A genome-wide association study in progressive multiple sclerosis. Mult Scler J 18(10):1384–1394.  https://doi.org/10.1177/1352458512439118 CrossRefGoogle Scholar
  19. Martínez-Cortés G, Salazar-Flores J, Haro-Guerrero J, Rubi-Castellanos R, Velarde-Félix JS, Muñoz-Valle JF, López-Casamichana M, Carrillo-Tapia E, Canseco-Avila LM, Bravi CM, López-Armenta M, Rangel-Villalobos H (2013) Maternal admixture and population structure in Mexican-Mestizos based on mtDNA haplogroups. Am J Phys Anthropol 151(4):526–537.  https://doi.org/10.1002/ajpa.22293 CrossRefPubMedGoogle Scholar
  20. McKay KA, Kwan V, Duggan T, Tremlett H (2015) Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int 2015:1–11.  https://doi.org/10.1155/2015/817238 CrossRefGoogle Scholar
  21. Melcon MO, Melcon CM, Bartoloni L et al (2013) Towards establishing MS prevalence in Latin America and the Caribbean. Mult Scler 19(2):145–152.  https://doi.org/10.1177/1352458512441985 CrossRefPubMedGoogle Scholar
  22. O’Rourke DH, Raff JA (2010) The human genetic history of the Americas: the final frontier. Curr Biol 20(4):R202–R207.  https://doi.org/10.1016/j.cub.2009.11.051 CrossRefPubMedGoogle Scholar
  23. Ordoñez G, Romero S, Orozco L, Pineda B, Jiménez-Morales S, Nieto A, García-Ortiz H, Sotelo J (2015) Genomewide admixture study in Mexican Mestizos with multiple sclerosis. Clin Neurol Neurosurg 130:55–60.  https://doi.org/10.1016/j.clineuro.2014.11.026 CrossRefPubMedGoogle Scholar
  24. Prat E, Tomaru U, Sabater L, Park DM, Granger R, Kruse N, Ohayon JM, Bettinotti MP, Martin R (2005) HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol 167(1-2):108–119.  https://doi.org/10.1016/j.jneuroim.2005.04.027 CrossRefPubMedGoogle Scholar
  25. Rangel-Villalobos H, Muñoz-Valle JF, González-Martín A, Gorostiza A, Magaña MT, Páez-Riberos LA (2008) Genetic admixture, relatedness, and structure patterns among Mexican populations revealed by the Y-chromosome. Am J Phys Anthropol 135(4):448–461.  https://doi.org/10.1002/ajpa.20765 CrossRefPubMedGoogle Scholar
  26. Rivera VM (2008) Esclerosis múltiple en Latinoamérica. Rev Española Escler Múltiple 9:17–23. http://www.revistaesclerosis.es/pdf/partes/v1_9dic08_2.pdf
  27. Rivera VM (2017) Multiple sclerosis in Latin Americans: genetic aspects. Curr Neurol Neurosci Rep 17(8):57.  https://doi.org/10.1007/s11910-017-0768-4 CrossRefPubMedGoogle Scholar
  28. Rivera V, Medina M, Duron R, Macías M (2014) Multiple sclerosis care in Latin America. Neurology 82(16):1660–1662.  https://doi.org/10.1212/WNL.0000000000000376 CrossRefPubMedPubMedCentralGoogle Scholar
  29. Rosati G (2001) The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22(2):117–139.  https://doi.org/10.1007/s100720170011 CrossRefPubMedGoogle Scholar
  30. Rubi-Castellanos R, Martínez-Cortés G, Muñoz-Valle JF et al (2009) Pre-hispanic Mesoamerican demography approximates the present-day ancestry of Mestizos throughout the territory of Mexico. Am J Phys Anthropol 139(3):284–294.  https://doi.org/10.1002/ajpa.20980 CrossRefPubMedGoogle Scholar
  31. Simpson S, Blizzard L, Otahal P, van der Mei I, Taylor B (2011) Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 82(10):1132–1141.  https://doi.org/10.1136/jnnp.2011.240432 CrossRefPubMedGoogle Scholar
  32. Smith KJ, Pyrdol J, Gauthier L, Wiley DC, Wucherpfennig KW (1998) Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med 188(8):1511–1520.  https://doi.org/10.1084/jem.188.8.1511 CrossRefPubMedPubMedCentralGoogle Scholar
  33. Sospedra M, Muraro PA, Stefanová I et al (2006) Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J Immunol 176:1951–1961.  https://doi.org/10.4049/jimmunol.176.3.1951 CrossRefPubMedPubMedCentralGoogle Scholar
  34. Tokunaga K, Ohashi J, Bannai M, Juji T (2001) Genetic link between Asians and native Americans: evidence from HLA genes and haplotypes. Hum Immunol 62(9):1001–1008.  https://doi.org/10.1016/S0198-8859(01)00301-9 CrossRefPubMedGoogle Scholar
  35. Vargas-Alarcon G, Granados J, Perez-Hernandez N et al (2011) HLA-class II genes in Mexican Amerindian Mayas: relatedness with Guatemalan Mayans and other populations. Immunol Investig 40(1):101–111.  https://doi.org/10.3109/08820139.2010.517588 CrossRefGoogle Scholar
  36. Villoslada P, Barcellos LF, Rio J, Begovich AB, Tintore M, Sastre-Garriga J, Baranzini SE, Casquero P, Hauser SL, Montalban X, Oksenberg JR (2002) The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol 130(1-2):194–201.  https://doi.org/10.1016/S0165-5728(02)00215-1 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • G. V. González-Enríquez
    • 1
  • B. M. Torres-Mendoza
    • 1
    • 2
  • J. Márquez-Pedroza
    • 2
    • 3
  • M. A. Macías-Islas
    • 3
    • 4
  • G. G. Ortiz
    • 5
  • J. A. Cruz-Ramos
    • 1
    • 6
  1. 1.Departamento de Disciplinas Filosóficas, Metodológicas e Instrumentales, Centro Universitario de Ciencias de la Salud (CUCS)Universidad de GuadalajaraGuadalajaraMexico
  2. 2.Laboratorio de Inmunodeficiencias y Retrovirus Humanos, División de Neurociencias, Centro de Investigación Biomédica de Occidente (CIBO)Instituto Mexicano del Seguro Social (IMSS)GuadalajaraMexico
  3. 3.Doctorado en Farmacología, CUCSUniversidad de GuadalajaraGuadalajaraMexico
  4. 4.Departamento de Neurología, Unidad Médica de Alta Especialidad (UMAE)-Hospital de Especialidades, Centro Médico Nacional de Occidente (CMNO)IMSSGuadalajaraMexico
  5. 5.Laboratorio de Desarrollo-Envejecimiento, Enfermedades Neurodegenerativas, División de NeurocienciasCIBO, IMSSGuadalajaraMexico
  6. 6.Instituto Jalisciense de CancerologíaGuadalajaraMexico

Personalised recommendations